Chikungunya Vaccine Shows Strong Protection in Adults Over 65
Phase 3 trial demonstrates 87% protection rate with single-dose vaccine in older adults most vulnerable to severe disease.
Summary
A phase 3 trial of 413 adults aged 65+ found that the Vimkunya chikungunya vaccine provided strong protection against this mosquito-borne disease. The single-dose vaccine achieved 87% seroprotection rates at 22 days, with protection lasting at least 6 months. This is particularly important since older adults face higher risks of severe chikungunya outcomes including death. The vaccine was well-tolerated with mostly mild side effects and no serious vaccine-related adverse events.
Detailed Summary
Chikungunya virus poses serious health risks to older adults, who experience more severe disease outcomes and higher mortality rates than younger populations. This phase 3 randomized controlled trial evaluated the safety and effectiveness of Vimkunya, a virus-like particle vaccine, in 413 adults aged 65 and older across ten U.S. sites.
Participants received either a single intramuscular dose of the vaccine or placebo. Researchers measured neutralizing antibody levels at multiple timepoints to assess immune response. The vaccine demonstrated impressive efficacy, achieving protective antibody levels in 82% of participants by day 15 and 87% by day 22 after vaccination.
Protection remained robust at six months, with 76% of vaccinated participants maintaining protective antibody levels. Importantly, immune responses were similar between those aged 65-74 and those 75 and older, suggesting the vaccine works well across the older adult age spectrum.
Safety results were reassuring, with adverse events being mostly mild to moderate and short-lived. No vaccine-related serious adverse events or deaths occurred during the 183-day follow-up period.
These findings represent a significant advance in protecting vulnerable older adults from chikungunya, a debilitating disease that can cause prolonged joint pain and disability. The single-dose regimen offers practical advantages for vaccination programs targeting this high-risk population.
Key Findings
- Single vaccine dose achieved 87% protection rate in adults 65+ within 22 days
- Protection remained strong at 76% after 6 months of follow-up
- Similar immune responses in 65-74 and 75+ age groups
- No serious vaccine-related adverse events or deaths occurred
- Most side effects were mild to moderate and short-duration
Methodology
Phase 3 randomized, double-blind, placebo-controlled trial with 413 participants aged 65+ at ten U.S. sites. Participants received single intramuscular dose of vaccine or placebo with neutralizing antibody measurements at multiple timepoints through 183 days.
Study Limitations
Study limited to U.S. population and 6-month follow-up period. Long-term durability of protection beyond 6 months remains unknown. Real-world effectiveness against circulating virus strains needs confirmation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.